Insulet (NASDAQ:PODD) Now Covered by Stifel Nicolaus

Stifel Nicolaus started coverage on shares of Insulet (NASDAQ:PODD) in a report published on Tuesday morning, MarketBeat.com reports. The firm issued a buy rating and a $370.00 target price on the medical instruments supplier’s stock.

A number of other brokerages have also recently commented on PODD. Rothschild & Co Redburn raised their price target on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research note on Friday, October 3rd. Canaccord Genuity Group raised their price target on shares of Insulet from $353.00 to $399.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Leerink Partners boosted their target price on Insulet from $339.00 to $355.00 and gave the stock an “outperform” rating in a report on Tuesday, October 14th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average target price of $352.11.

Insulet Stock Up 0.6%

Shares of PODD opened at $328.97 on Tuesday. The stock has a market cap of $23.16 billion, a price-to-earnings ratio of 99.99, a P/E/G ratio of 2.73 and a beta of 1.40. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet has a 12 month low of $226.50 and a 12 month high of $353.50. The company has a 50-day moving average price of $327.04 and a two-hundred day moving average price of $303.28.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company’s revenue for the quarter was up 32.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts predict that Insulet will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.39% of the company’s stock.

Institutional Trading of Insulet

Hedge funds and other institutional investors have recently modified their holdings of the stock. True Wealth Design LLC increased its holdings in shares of Insulet by 288.0% in the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 72 shares in the last quarter. Zions Bancorporation National Association UT bought a new position in Insulet in the first quarter valued at approximately $26,000. Larson Financial Group LLC boosted its stake in Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 81 shares during the last quarter. Golden State Wealth Management LLC boosted its stake in Insulet by 202.9% in the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after acquiring an additional 69 shares during the last quarter. Finally, SouthState Corp boosted its stake in Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 76 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.